SpringWorks Therapeutics (NASDAQ:SWTX) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in SpringWorks Therapeutics stock on January 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of ICF International NASDAQ: ICFI on 2/3/2025.
• Purchased $15,001 - $50,000 in shares of CACI International NYSE: CACI on 1/31/2025.
• Purchased $50,001 - $100,000 in shares of Hawaiian Electric Industries NYSE: HE on 1/31/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of Agios Pharmaceuticals NASDAQ: AGIO on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Paragon 28 NYSE: FNA on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of U.S. Physical Therapy NYSE: USPH on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Crinetics Pharmaceuticals NASDAQ: CRNX on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Lantheus NASDAQ: LNTH on 1/28/2025.

SpringWorks Therapeutics Trading Down 2.0 %

SpringWorks Therapeutics stock traded down $1.16 during mid-day trading on Friday, hitting $57.43. The stock had a trading volume of 2,778,360 shares, compared to its average volume of 1,684,477. The stock has a 50-day simple moving average of $39.35 and a two-hundred day simple moving average of $36.86. The stock has a market capitalization of $4.27 billion, a PE ratio of -14.80 and a beta of 0.81. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $60.00.

Analyst Ratings Changes

SWTX has been the topic of a number of research analyst reports. Wedbush reaffirmed an "outperform" rating and set a $77.00 price target on shares of SpringWorks Therapeutics in a research report on Monday, February 10th. Evercore ISI lifted their target price on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an "outperform" rating in a research report on Wednesday. Guggenheim dropped their target price on SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $74.00 price target on shares of SpringWorks Therapeutics in a research report on Wednesday. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $70.83.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SWTX. Huntington National Bank grew its holdings in shares of SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after purchasing an additional 192 shares in the last quarter. AlphaQuest LLC lifted its position in shares of SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock worth $36,000 after buying an additional 414 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of SpringWorks Therapeutics during the 4th quarter worth $45,000. KBC Group NV lifted its position in shares of SpringWorks Therapeutics by 59.1% during the 4th quarter. KBC Group NV now owns 2,634 shares of the company's stock worth $95,000 after buying an additional 978 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of SpringWorks Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company's stock worth $87,000 after buying an additional 474 shares during the last quarter.

Insider Buying and Selling at SpringWorks Therapeutics

In other news, COO Badreddin Edris sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total value of $839,400.00. Following the transaction, the chief operating officer now owns 209,600 shares in the company, valued at $8,796,912. This trade represents a 8.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel Lynch sold 175,000 shares of SpringWorks Therapeutics stock in a transaction on Monday, February 10th. The stock was sold at an average price of $54.46, for a total value of $9,530,500.00. Following the sale, the director now owns 130,944 shares in the company, valued at $7,131,210.24. This trade represents a 57.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 302,750 shares of company stock worth $16,139,410. 7.61% of the stock is currently owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.